Reuters logo
BRIEF-Brainstorm reaches agreement with FDA to proceed with NurOwn phase 3 trial
December 19, 2016 / 7:16 AM / 10 months ago

BRIEF-Brainstorm reaches agreement with FDA to proceed with NurOwn phase 3 trial

Dec 19 (Reuters) - Brainstorm Cell Therapuetics Inc

* Sees to commence an international phase 3 trial with NurOwn in ALS in 2017

* plans to submit application in Israel that will allow patient access to NurOwn as treatment granted hospital exemption

* Says has reached general agreement with FDA to proceed to a phase 3 trial

* sees submission of application for hospital exemption for NurOwn in Israel successful end of phase 2 meeting in 2017

* Brainstorm reports on successful end of phase 2 meeting with FDA, upcoming phase 3 trial and planned application for hospital exemption for NurOwn Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below